Accumulating evidence has shown that long noncoding RNAs (lncRNAs) are involved in 25 several biological processes, including immune responses. However, the role of lncRNAs in 26 antiviral innate immune responses remains largely unexplored. Here, we identify an 27 uncharacterized human lncRNA, antivirus and activate neutrophil (AVAN), that is significantly 28 up-regulated upon virus infection. Mechanistically, nuclear lncRNA-AVAN positively 29 regulates the transcription of forkhead box O3A (FOXO3a) in cis by associating with its 30 promoter and inducing chromatin remodeling to promote neutrophil chemotaxis. Furthermore, 31 we also found that cytoplasmic lncRNA-AVAN directly binds tripartite motif containing 25 32 (TRIM25) and enhances the association of TRIM25 and Retinoic acid inducible gene-1 33 proteins (RIG-I) and the ubiquitylation of RIG-I, thereby promoting TRIM25-and 34 RIG-I-mediated antiviral innate immune signaling. Collectively, these findings highlight the 35 potential clinical implications of lncRNA-AVAN as a key positive regulator of the antiviral 36 innate immune response and a promising target for developing broad antiviral therapeutics. 37 38
Introduction
exert their roles in regulating chromatin accessibility, mRNA stability and protein activity by 48 interacting with chromatin DNA, mRNAs or proteins (15) (16) (17) (18) . With the discovery and 49 characterization of an increasing number of lncRNAs, several mechanisms of these lncRNAs 50 in virus-host interactions have been elucidated (19) , however, many others remain 51 uncharacterized. 52 Influenza A virus (IAV) is a leading cause of respiratory-related morbidity and mortality, 53 posing a substantial threat to global health (20) . However, some mechanisms underlying 54 IAV-host interactions remain unclear. Neutrophils provide one of the early lines of innate 55 immunity and defense against invading microorganisms, which contribute to the fine 56 regulation of the inflammatory and antiviral immune responses (21-23). Increasing evidence 57 suggests that neutrophils are also prominent components of the inflammatory and immune 58 responses during virus infection. Neutrophils are rapidly recruited to sites of infection during 59 the innate immune response to IAV (24-26). In addition, neutrophils can produce and release a 60 large variety of cytokines and chemokines (22) , which enables them to significantly influence 61 antiviral defense (27) . During virus infection, chemokines play a crucial role in neutrophil activation and chemotaxis (28). However, how lncRNA functions in this process is largely 63 unknown. 64 Intracellular RIG-I-like receptors (RLRs), namely, RIG-I, MDA5, and LGP2, are 65 well-defined single-stranded viral RNA sensors that play a pivotal role in host antiviral 66 activity by initializing the rapid production of type I interferons (IFN) and cytokines (29) . 67 RIG-I is a key sensor of paramyxoviruses, influenza virus, hepatitis C virus, and Japanese 68 encephalitis virus (30). The binding of viral RNA to the RIG-I C-terminal regulatory domain 69 results in a conformational change that, in turn, enables RIG-I binding to the signal adaptor 70 MAVS (also called VISA, IPS-1, or CARDIF) through N-terminal caspase recruitment 71 domains (CARDs). Such binding enhances the phosphorylation of IRF3 and eventually leads 72 to the production of type I IFN and inflammatory cytokines (31). However, little is known 73 about the roles of lncRNAs in IAV-infected patients or the mechanisms of lncRNA activity 74 and host antiviral immune responses. 75 In this study, we profile the lncRNAs of IAV-infected patient neutrophils and identify a 76 human lncRNA, designated AVAN, which plays a critical role in anti-IAV infection. 77 Functional experiments demonstrate that AVAN up-regulates FOXO3a expression to promote 78 neutrophil chemotaxis and recruitment. In addition, AVAN enhances the activation of the 79 RIG-I-mediated antiviral response by directly binding to TRIM25. These results show that an 80 unannotated lncRNA, AVAN, functions to maintain innate immune homeostasis of antiviral 81 immunity during IAV infection. 82 LncRNA expression is regulated by the influenza A (H7N9) virus in human neutrophils. 84 Neutrophils, the prototypic cells of the innate immune system, are reported to play a 85 pivotal role in the innate immune response to IAV (21-23). To explore the roles of host 86 lncRNAs during IAV infection, we profiled whole transcriptional alterations using RNA-Seq 87 in neutrophil samples from patients infected with IAV in the acute stage and their matched 88 recovery-stage samples (GSE108807). We identified a total of 404 differentially expressed 89 protein-coding genes (FC>2, p<0.05), including 234 up-regulated and 170 down-regulated 90 genes, in each patient sample ( Fig S1) . The differentially expressed genes were strongly 91 associated with the immune response, inflammatory response and innate immune response 92 according to Gene ontology (GO) analysis ( Fig 1A) . We then mapped the detected lncRNAs 93 to the human genome (UCSC version hg19) and the NONCODE V3.0 database and found an 94 average of 240 up-regulated (range from 164 to 357) and 193 down-regulated (range from 95 158 to 257) novel lncRNAs in acute-stage influenza patients compared with their 96 recovery-stage counterparts (FC>2, p<0.05) and subjected them to a cluster analysis ( Fig 1B) . 97 To investigate the association between lncRNAs and IAV infection, in silico analysis 98 identified 26 novel lncRNAs candidates with notably aberrant expression ( Fig 1C) . To 99 confirm the expression of these lncRNAs, we separated the neutrophils and monocytes from 100 healthy volunteers and infected the cells with IAV for 12 h and found that XLOC_040025 101 (AVAN) was most significantly up-regulated after IAV challenge ( Fig 1D, E) . We also infected 102 human alveolar epithelial cells (A549) with IAV and measured the expression of the 26 103 lncRNAs and found that AVAN was most strongly up-regulated after IAV infection ( Fig 1F) . 106 We then performed qRT-PCR to quantify AVAN expression in the RNA-Seq samples and 107 found that the results were consistent with the RNA-Seq data ( Fig S2A) . Thus, AVAN was 108 chosen for subsequent investigation. To further confirm the expression of AVAN in 109 IAV-infected patients, we collected blood samples from 63 additional IAV-positive patients 110 and measured the expression of AVAN, which was significantly up-regulated in the neutrophils 111 of these patients (Fig 2A; Table S1 ). Similarly, AVAN was up-regulated in A549 cells after 112 infection with multiple sub-strains of IAV and several other viruses, including Sendai virus 113 (SeV) and respiratory syncytial virus (RSV) ( Fig 2B) . Moreover, AVAN expression was 114 significantly up-regulated upon IAV challenge in a time-and dose-dependent manner in A549 115 cells ( Fig 2C, D) . Moreover, AVAN expression was also significantly up-regulated in a time- 116 and dose-dependent manner in the human promyelocytic leukemia cell line (HL60), which is 117 often a substitute for neutrophils, upon IAV challenge ( Fig S2B, C) . Subcellular fractionation 118 followed by qRT-PCR in IAV-infected A549 cells revealed that the amount of AVAN localized 119 in the cytoplasm was nearly as same as the one in nucleus (Fig 2E, Fig S2D) . Besides, we 120 performed RNA fluorescence in situ hybridization (RNA-FISH) with two specific probes in 121 IAV-uninfected and -infected A549 cells and found that AVAN localized in the cytoplasm and 122 nucleus were almost the same abundance ( Fig 2F) . In addition, we constructed competitive 123 association FISH to display the specific distribution of AVAN. When adding free 124 labeling-probes, the fluorescent dye from biotin labeling-probes was weaken ( Fig S2E) . AVAN 125 exhibits no protein-coding potential according to ORF finder (32) and the coding potential calculator (33) ( Fig S2F) . Only one transcript variant (approximately 500 nt) of AVAN was 127 found in A549 cells, and it was found to be up-regulated upon IAV infection using northern 128 blot analysis ( Fig 2G) . The exact transcript length (517 nt) of AVAN was confirmed by 5' and 129 3' RACE (Table S2) , which revealed that AVAN is polyadenylated ( Fig S2G) . Taken together, Table S3 -S8), suggesting that AVAN participates in innate antiviral immunity. To 140 identify the functions of AVAN, we generated AVAN-overexpressing A549 cells ( Fig 3A) and 141 found that viral replication was strongly inhibited ( Fig 3B) . In contrast, virus titer was 142 up-regulated following AVAN knockdown with two specific siRNAs ( Fig Fig 3C) . 150 To confirm this result, we performed ELISA to measure IFN-α and IFN-β protein expression 151 and found that IFN-α and IFN-β were strongly up-regulated in AVAN-overexpressing A549 152 cells during IAV infection ( Fig 3D) . Conversely, these phenomena were abolished by 153 knocking down AVAN (Fig 3J, K) . 154 The above GSEA data and GO analysis showed that the genes related to AVAN were also 155 significantly enriched in chemotaxis and immune cell activation ( Fig S4A, Table S9 , S10), the Fig 3M, N) . To verify our hypothesis, we next overexpressed or knocked down harvested at the indicated times, and transcript and protein levels of IL-8 were measured. The 173 results from HL60 cells were consistent with those obtained in A549 cells (Fig S4D, F) . 174 Collectively, these data indicate that lncRNA-AVAN plays a vital role in antiviral responses by 175 positively regulating type I IFN induction and neutrophil chemotaxis. Table S11 ). Most of these divergent 182 genes were associated with antiviral innate immune responses and inflammatory diseases 183 according to Reactome pathway analysis ( Fig 4B) and FunDO diseases analysis ( Fig S5) . 184 Notably, genes associated with immune system IFN signaling and cytokine signaling were 185 markedly up-regulated in cells with ectopic AVAN expression compared with control cells, 186 including chemokines and ISGs (IFN stimulated genes) ( Fig 4C) . These significantly 187 up-regulated genes, including MX1, ISG15, IFIT2, OASL, IFIM3, TNFAIP3, CXCL2 and 188 CCL5, were confirmed by qRT-PCR ( Fig 4D) . These data again reveal that AVAN strongly 189 participates in antiviral innate immune processes and neutrophil chemotaxis. Previous experiments demonstrated that AVAN is located in the cytoplasm (Fig 2E, 2F) . 232 To investigate the molecular mechanism of AVAN in the cytoplasm, RNA pull-down assays 233 using biotin-labeled AVAN or AVAN antisense control followed by mass spectrometry (MS) 234 analysis were performed. The E3 ubiquitin ligase TRIM25, an RNA-binding protein, was 235 found to bind AVAN in IAV-infected A549 cells compared with the AVAN antisense control ( Fig 6A) . This result was confirmed by AVAN RNA pull-down western blot experiments (Fig   237   6B ). Besides, ChIRP followed by western blot revealed that AVAN-specific probes could pull 238 down TRIM25 while LacZ couldn't ( Fig 6C) . To validate the interaction between AVAN and 239 TRIM25, we immunoprecipitated TRIM25 from IAV-infected A549 cells and quantified the Fig 6F) . Furthermore, to explore the TRIM25 binding site on AVAN RNA, three 247 truncated probes from AVAN were used for RNA pull-down assay. The result indicated that 248 the TRIM25-binding activity mapped between nucleotides 1 and 200 ( Fig 6G) . Together, 249 these findings indicate that AVAN physically interacts with TRIM25 and that the B box/central 250 CCD of TRIM25 and 1-200nt of AVAN contribute to this association. 251 To test whether AVAN enhances the IFN-mediated antiviral innate immune response 252 through TRIM25 and RIG-I signaling, we knocked down endogenous TRIM25 in HEK-293T 253 cells and observed a markedly reduced effect of ectopic AVAN expression on the activation of 254 IFNB1-responsive reporters in the context of IAV infection ( Fig S7A) . RIG-I is 255 polyubiquitinated by TRIM25, which attaches K63-linked polyubiquitin to the sensor (47), 256 Previous study showed that a stabilization of TRIM25-RIG-I interaction is important for a 257 sustained antiviral IFN response (48). We next examined the effect of AVAN on the interaction between TRIM25 and RIG-I. We found that ectopically expressing AVAN markedly enhanced 259 the association between TRIM25 and RIG-I upon IAV infection ( Fig 6H) . Additionally, 260 different fragments of AVAN were overexpressed in A549. We observed that P1 (1-200nt) 279 To further investigate the in vivo effect of AVAN on IAV pathogenesis, we constructed an AVAN-containing AAV2/9 vector and a control vector, which were then delivered into 281 4-week-old C57L/B6 mice via intranasal (i.n.) administration. We found that AVAN was 282 ectopically expressed in the lung of AAV2/9-AVAN treated mice ( Fig 7A) . Strikingly, after 283 BJ501 infection, the groups pretreated with AAV2/9-AVAN exhibited significantly increased 284 survival rates and reduced body weight loss at 10 days post-infection compared with the 285 control group (Fig 7B, C) . Furthermore, lung edema, measured as the wet-to-dry ratio of 286 whole lung, was ameliorated ( Fig 7D) , and improved lung histopathology was observed in 287 infected mice pretreated with AAV2/9-AVAN ( Fig 7E, F) . Moreover, the virus titer from the 288 lungs of infected mice was also significantly reduced in AAV2/9-AVAN-treated mice 289 compared with that in control mice (Fig 7G, H) . Although AVAN triggers FOXO3a expression 290 in the nucleus to enhance neutrophil chemotaxis in vitro, we did not observe that AVAN 291 promotes FOXO3a expression in vivo (data not shown). This finding may result from the low 292 conservation of AVAN between humans and mice. Consistent with the association in human, 293 we found that AVAN also bind to rodent Trim25 through RNA pull-down using mouse tissue 294 ( Fig 7I) . In addition, AAV2/9-AVAN promote type I IFN expression in vivo ( Fig 7J) . Taken (Fig 3) , speculated that lncRNA AVAN is critical in the IFN induction pathway. 368 To the best of our knowledge, our work represents the first identification of lncRNA-AVAN as 369 a novel partner of TRIM25 and demonstrates that AVAN suppresses IAV replication via 370 TRIM25-RIG-I-dependent antiviral pathways. 371 In conclusion, we provide the first lncRNA landscape of IAV-infected patient neutrophils 372 and identify the function of AVAN, a novel lncRNA, in the innate antiviral immune response. 373 AVAN can enhance the chemotaxis of neutrophils by promoting FOXO3a expression in cis. 374 On the one hand, AVAN can serve as a positive regulator of RIG-I signaling by directly 375 binding TRIM25 and enhancing the association between TRIM25 and RIG-I in trans. (Fig 8) . 376 Of course, the mechanism of action of AVAN in vivo (transgenic mice) during IAV and its Supplementary Table S12 . Cytokines levels were measured using an ELISA kit (Dakewe, Beijing).
AVAN is preferentially up-regulated following virus infection

AVAN protects mice from influenza A infection in vivo
Neutrophil chemotaxis assay 428
In vitro chemotactic assays were performed in 24-well Millicell hanging-cell culture inserts 429 (Millipore). Briefly, the cells were starved by incubation for 18-24 h prior to the assay in Western blotting 452 All cells were lysed in RIPA (Solarbio) supplemented with protease and phosphatase inhibitor 453 cocktail (100×, Thermo Fisher) and lysed for 10 min on ice. The supernatant was mixed with 454 1/4 volume of 5× loading dye. The mixtures were then heated at 95°C and stored at -80°C. 455 The samples were separated by SDS-PAGE and transferred onto nitrocellulose membranes. 456 The membranes were then blocked with 5% nonfat milk (BD) in 1× Tris-buffered saline and 457 0.1% Triton 100 for 1 h while shaking at room temperature. Next, the membranes were 458 incubated with primary antibodies and horseradish peroxidase-conjugated secondary 459 antibodies. Bands were visualized using the Kodak film exposure detection system. The film 460 was scanned, and the band intensity was analyzed using Quantity One software.
462
Quantitative real-time PCR 463 Total RNA was extracted from cultured cells using TRIzol reagent (Invitrogen). cDNA was 464 generated by reverse transcription with commercial PrimeScript RT Master Mix (Takara). 465 Primer pairs (Table S12) Table   506 S12. ChIP was performed as described (63). The ChIP-enriched FOXO3a promoter was 507 quantified by qPCR using the primer pairs listed in Table S12 . 
